In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Elan acquires Dura Pharmaceuticals for $1.69bn

04 Oct 2000

Executive Summary

Elan has acquired Dura Pharmaceuticals (respiratory pharmaceuticals) in a tax-free, stock-for-stock transaction valued at $1.69bn. Dura shareholders will receive 0.6715 of an Elan ADS in exchange for one share, or $37.85, a (pr)38% premium based on the market average.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Stock

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By